Jazz Pharmaceuticals plc (JAZZ)

NMS – Real Time Price. Currency in USD

249.50

+1.52 (0.61%)

Market open: Aug 12, 2026, 10:44 AM EDT

248.05

+0.07 (0.03%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

10.08.2026

Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Jazz Pharmaceuticals said on Monday it would buy privately held Actio Biosciences in a deal valued at up to $1.32 billion, adding an experimental treatment for ‌a rare inherited form of epilepsy that has no approved therapies.

10.08.2026

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction includes $820 million upfront payment DUBLIN and SAN DIEGO, Aug. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have entered into a definitive agreement for Jazz to acquire privately-held Actio Biosciences for $820 million upfront and up to $500 million in contingent consideration. Actio Biosciences' lead clinical asset is ABS-1230, a novel, first-in-class small molecule precision therapy KCNT1 ion channel inhibitor.

07.08.2026

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

06.08.2026

JAZZ vs. TECH: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?

05.08.2026

Jazz Pharmaceuticals' Re-Rating Story Has Legs

Jazz Pharmaceuticals has delivered strong year-to-date performance, raising full-year revenue guidance. JAZZ's oxybate franchise, led by Xywav, continues double-digit growth despite the full generic Xyrem launch, driving a significant guidance increase. Ziihera's potential first-line GEA approval this month could unlock a large new revenue stream and accelerate sequential growth.

04.08.2026

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.

04.08.2026

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) on Monday reported better-than-expected second-quarter sales results and raised its FY26 sales guidance above estimates.

Videos

No Data

There is no data to display

Press releases

10.08.2026

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

03.08.2026

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

– Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) – – Company raises 2026 revenue guidance – – Prepared to launch Ziihera® in HER2+ 1L GEA immediately following FDA approval – – Xywav® revenues grew 13% YoY with 525 net patient adds in 2Q26 – – Epidiolex® revenues grew 16% YoY – DUBLIN, Aug. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026. "Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.

Jazz Pharmaceuticals plc (JAZZ)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Jazz Pharmaceuticals plc (JAZZ)

Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

JAZZ vs. TECH: Which Stock Is the Better Value Option?

Jazz Pharmaceuticals' Re-Rating Story Has Legs

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Videos

No Data

Press releases

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

JAZZ vs. TECH: Which Stock Is the Better Value Option?

Jazz Pharmaceuticals' Re-Rating Story Has Legs

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Videos

No Data

Press releases

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

Search stocks

Jazz Pharmaceuticals plc (JAZZ)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Jazz Pharmaceuticals plc (JAZZ)

Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

JAZZ vs. TECH: Which Stock Is the Better Value Option?

Jazz Pharmaceuticals' Re-Rating Story Has Legs

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Videos

No Data

Press releases

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

JAZZ vs. TECH: Which Stock Is the Better Value Option?

Jazz Pharmaceuticals' Re-Rating Story Has Legs

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Videos

No Data

Press releases

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results